Balanced news tone
News Sentiment
PYXS sentiment intelligence
Pyxis Oncology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+1.5% over one week, +51.7% over four weeks, trend active, and near fair-value range.
Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Pyxis Oncology raises $50 million in private placement
Pyxis Oncology announced a private placement to raise approximately $50 million, led by BVF Partners L.P. The financing includes warrants that could generate an additional $64 million and is expected to extend the company's cash runway into Q2 2027. Pyxis Oncology also updated it
- Tone
- Positive 71/100
- Event
- Balance sheet
- Published
- 30 Jun 2026 12:39
- Source
- Investing.com
Pyxis Oncology raises up to $114M to fund MICVO trial updates
Pyxis Oncology (Nasdaq: PYXS) announced a private placement deal potentially worth $114 million, including $50 million upfront and up to $64 million from warrant exercises. This financing, led by BVF Partners, aims to extend the company's cash runway into Q2 2027 and fund key cli
- Tone
- Positive 72/100
- Event
- Deals and strategy
- Published
- 30 Jun 2026 11:39
- Source
- Stock Titan
Pyxis Oncology Announces Up to $114 Million Private
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- GlobeNewswire
Pyxis Oncology, Inc.(NasdaqGS: PYXS) added to Russell 3000E Growth Benchmark
Pyxis Oncology, Inc. (NasdaqGS: PYXS) has been added to the Russell 3000E Growth Benchmark, as announced on June 29, 2026. This news follows a series of other updates for the clinical-stage oncology company, including a recent private placement, changes in its CEO and other execu
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 16:39
- Source
- www.marketscreener.com
Pyxis Oncology, Inc. Actuals & Estimates (NASDAQ:PYXS)
This article provides an overview of Pyxis Oncology, Inc. (NASDAQ: PYXS) stock, including its current price, historical performance, analyst forecasts, and various financial metrics. It details the stock's volatility, market capitalization, and upcoming earnings report, along wit
- Tone
- Positive 65/100
- Event
- Earnings
- Published
- 26 Jun 2026 02:39
- Source
- TradingView
Penny Stocks To Watch For Growth In June 2026
This article identifies three penny stocks—Anixa Biosciences (ANIX), Pyxis Oncology (PYXS), and Xtra-Gold Resources (XTGR.F)—as potential growth opportunities for June 2026. These companies, despite being in early stages or pre-revenue, demonstrate strong financial health, promis
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 18 Jun 2026 17:10
- Source
- Simply Wall Street
Pyxis Oncology (PYXS) shareholders elect Class II directors and ratify Ernst & Young as 2026 auditor
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Market source
Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives
- Tone
- Negative 34/100
- Event
- Balance sheet
- Published
- 16 May 2026 07:00
- Source
- simplywall.st
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 11:00
- Source
- GlobeNewswire
Pyxis Oncology Reports First Quarter 2026 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- GlobeNewswire
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Pyxis Oncology to Participate in Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 11:30
- Source
- GlobeNewswire
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 May 2026 20:05
- Source
- GlobeNewswire
Pyxis brings in former ImmunoGen dealmaker to advance MICVO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- Stock Titan
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 05 May 2026 11:33
- Source
- MT Newswires
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 20:05
- Source
- GlobeNewswire
PYXS | Pyxis Oncology, Inc. Common Insider Trading
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Apr 2026 09:51
- Source
- Quiver Quantitative
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Pyxis Oncology (PYXS) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 00:33
- Source
- Stock Titan
Pyxis Oncology (PYXS) Stock Price, News & Analysis $PYXS
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Oct 2021 15:53
- Source
- MarketBeat